Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma

References

• Dimopoulos M, Zervas K, Kouvatseas G, et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann One 2001;12:991–995.
   PubMed Web of Science ®Google Scholar
• Anagnostopoulos A, Weber D, Rankin K, et al. Thalidomide and dexamethasone for resistant multiple myeloma. Brit J Haemat 2003;121:768–771.
   PubMed Web of Science ®Google Scholar
• Rajkumar S, Hayman S, Gertz M, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 200220:4319–4323.
   PubMed Web of Science ®Google Scholar
• Weber D, Rankin K, Gavino M, et al. Thalidomide alone or with dexamethasone for previously untreated multiple myel-oma. J Clin Oncol 2003;21:16–19.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Barlogie B, Berenson J, et al. A phase II study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003348:2609–2617.
   PubMed Web of Science ®Google Scholar
• Richardson P, Chanan-Khan A, Schlossman R. Phase II trial of single agent bortezomib in patients with previously untreated multiple myeloma. Blood 2004104:104a, ( abstract 336).
   Web of Science ®Google Scholar
• Attal M, Harousseau J, Stoppa A, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Eng J Med 1996; 335:91–97.
   PubMed Web of Science ®Google Scholar
• Child J, Morgan G, Davies F, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Eng J Med 2003;348:1875–1883.
   PubMed Web of Science ®Google Scholar
• Singhal S, Powles R, Sirohi B, et al. Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and auto transplantation in myeloma. Bone Marrow Transplant 2002;30:673–679.
   PubMed Web of Science ®Google Scholar
• Alexanian R, Weber D, Delasalle K, et al. Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma. Bone Marrow Transplant 2004; 34: 229–234.
   PubMed Web of Science ®Google Scholar
• Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Brit J Haemat 1998;102:1115–1123.
   PubMed Web of Science ®Google Scholar
• Bradwell A, Carr-Smith H, Mead G, et al. Serum test for assessment of patients with Bence Jones myeloma. Lancet 2003;361:489–491.
   PubMed Web of Science ®Google Scholar
• Alexanian R, Weber D, Giralt S, et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 2001; 27: 1037–1043.
   PubMed Web of Science ®Google Scholar
• Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565–1571.
   PubMed Web of Science ®Google Scholar
• Rajkumar S, Blood E, Vesole D. A randomized phase II trial of thalidomide plus dexamethasone versus dexamethasone in newly diagnosed multiple myeloma. J Clin Oncol 2004; 22: 560s, ( abstract).
   PubMed Web of Science ®Google Scholar
• Orlowski RZ, Voorhees PM, Garcia RA, EC, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005;105:3058–3065.
   PubMed Web of Science ®Google Scholar
• Zangari M, Barlogie B, Jacobson J. VTD regimen effects a 57% PR rate among 56 patients with relapsing myeloma. Blood 2003;102:236a, ( abstract).
   Web of Science ®Google Scholar
• Yang H, Swift R, Sadler K. A phase 1/II trial of velcade and melphalan combination therapy for patients with relapsed or refractory multiple myeloma. Blood 2003;102:235a ( abstract).
   Web of Science ®Google Scholar
• Oakervee H, Popat R, Curry N, et al. PAD combination therapy for previously untreated patients with multiple myeloma. Br J Haemat 2005;129:755–762.
   PubMed Web of Science ®Google Scholar
• Jagannath S, Dude B, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Brit J Haemat 2005;129:776–783.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Bradner JE, Wong J, et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA 2005;102:8567–8572.
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 2002;99:14374–14379.
   PubMed Web of Science ®Google Scholar
• Turk BD, Jiang H, Liu JO. Binding of thalidomide to alpha I-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production. Proc Natl Acad Sci USA 1996;93:7552–7556.
   Google Scholar
• Vacca A, Scavelli C, Montefusco V, et al. Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. J Clin Oncol 2005;23:5334–5346.
   PubMed Web of Science ®Google Scholar
• Chauhan D, Hideshima T, Pandey P, et al. Cytochrome c-dependent and -independent induction of apoptosis in multiple myeloma cells. J Biol Chemistry 1997; 272: 29995–29997.
   PubMed Web of Science ®Google Scholar
• Richardson P, Schlossman R, Weller E, et al. Immunomodu-latory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002;100:3063–3067.
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Weber D, Chen C. Evaluating oral lenalidomide and dexamethasone versus placebo and dexa-methasone in patients with relapsed or refractory multiple myeloma. Haematologica 2005;90:160 ( abstract).
   Google Scholar
• Rajkumar S, Hayman S, Lacy M, et al. Combination therapy with lenalidomide plus dexamethasone for newly diagnosed myeloma. Blood 2005;106:4050–4053.
   PubMed Web of Science ®Google Scholar
• Greipp P, San Miguel J, Dude B, et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412–3420.
   PubMed Web of Science ®Google Scholar